What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

What question did this study set out to answer?

To evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma.

March 22, 2026Open Access

PD-1/PD-L1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis

Key Points

To evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma.
Conducted a systematic literature search in PubMed, Embase, and the Cochrane Library.
Included nine studies with 883 patients, comprising 2 RCTs and 7 single-arm studies.
Analyzed outcomes such as progression-free survival and overall survival.
Median progression-free survival was 4.21 months, and median overall survival was 16.27 months.
The 1-year progression-free survival rate was 43%, while the 1-year overall survival rate was 80%.
Objective response rate was 45%, and disease control rate was 65%.

Abstract

Background: Nasopharyngeal carcinoma (NPC) has a poor prognosis, largely due to immune escape. The programmed cell death protein 1 (PD-1) receptor and its ligand, PD-L1, play critical roles in this immune evasion. Consequently, blocking the PD-1/PD-L1 pathway with immune checkpoint inhibitors has become an established therapeutic strategy. Methods: We performed a systematic literature search of PubMed, Embase, and the Cochrane Library for studies published up to November 14, 2024, investigating PD-1/PD-L1 inhibitors in recurrent or metastatic NPC. The analyzed outcomes included progression-free survival (PFS), overall survival (OS), 1-year PFS rate, 1-year OS rate, objective response rate, disease control rate, and adverse events (AEs). Results: Nine studies (comprising 10 datasets with 883 NPC patients) were included, consisting of 2 randomized controlled trials (RCTs) and 7 single-arm studies. The pooled analysis demonstrated a median PFS of 4.21 months (95% confidence interval CI: 2.47–5.95; P = .000; I 2 = 78.5%) and a median OS of 16.27 months (95% CI: 14.60–17.94; P = .000; I 2 = 0%). The pooled 1-year PFS rate was 43% (95% CI: 14%–73%; P = .004; I 2 = 99.1%), and the 1-year OS rate was 80% (95% CI: 70%–91%; P = .000; I 2 = 82.0%). The objective response rate was 45% (95% CI: 25%–64%; P = .000; I 2 = 96.8%), and the disease control rate was 65% (95% CI: 48%–82%; P = .000; I 2 = 96.4%). The incidence of any-grade AEs was 90% (95% CI: 74%–99%; P = .000; I 2 = 94.1%), while grade ≥3 AEs occurred in 34% of patients (95% CI: 12%–61%; P < .001; I 2 = 95.2%). No significant publication bias was identified. Conclusion: This meta-analysis summarizes the efficacy and safety profile of PD-1/PD-L1 inhibitors in recurrent or metastatic NPC. The findings highlight the need for additional randomized controlled trials to further validate the role of these therapies and provide an updated reference for clinical practice.

Read Full Paperexternally

AI에게 질문

Bookmark

View Full Paper